Multifactorial Approach to Predicting Resistance to Anthracyclines

蒽环类 医学 表阿霉素 乳腺癌 肿瘤科 内科学 曲妥珠单抗 雌激素受体 癌症 基因签名 基因表达 基因 生物 生物化学
作者
Christine Desmedt,Angelo Di Leo,Evandro de Azambuja,Denis Larsimont,Benjamin Haibe‐Kains,Jean Selleslags,Suzette Delaloge,Caroline Duhem,Jean-Pierre Kains,Birgit Carly,Marie Maerevoet,A. Vindevoghel,Ghizlane Rouas,Françoise Lallemand,Virginie Durbecq,Fátima Cardoso,Roberto Salgado,Rodrigo Kraft Rovere,Gianluca Bontempi,Stefan Michiels,Marc Buyse,Jean-Marie Nogaret,Yuan Qi,Fraser Symmans,Lajos Pusztai,Véronique D’Hondt,Martine Piccart‐Gebhart,Christos Sotiriou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:29 (12): 1578-1586 被引量:168
标识
DOI:10.1200/jco.2010.31.2231
摘要

Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER) -negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-α (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines.The TOP trial included 149 patients, 139 of whom were evaluable for response prediction analyses. The primary end point was pathologic complete response (pCR). TOP2A and gene expression profiles were evaluated using pre-epirubicin biopsies. Gene expression data from ER-negative samples of the EORTC (European Organisation for Research and Treatment of Cancer) 10994/BIG (Breast International Group) 00-01 and MDACC (MD Anderson Cancer Center) 2003-0321 neoadjuvant trials were used for validation purposes.A pCR was obtained in 14% of the evaluable patients in the TOP trial. TOP2A amplification, but not protein overexpression, was significantly associated with pCR (P ≤ .001 v P ≤ .33). We developed an anthracycline-based score (A-Score) combining three signatures: a TOP2A gene signature and two previously published signatures related to tumor invasion and immune response. The A-Score was characterized by a high negative predictive value ([NPV]; NPV, 0.98; 95% CI, 0.90 to 1.00) overall and in the human epidermal growth factor receptor 2 (HER2) -negative and HER2-positive subpopulations. Its performance was independently confirmed in the anthracycline-based arms of the two validation trials (BIG 00-01: NPV, 0.83; 95% CI, 0.64 to 0.94 and MDACC 2003-0321: NPV, 1.00; 95% CI, 0.80 to 1.00).Given its high NPV, the A-Score could become, if further validated, a useful clinical tool to identify those patients who do not benefit from anthracyclines and could therefore be spared the non-negligible adverse effects.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
guing完成签到 ,获得积分10
刚刚
李晨语发布了新的文献求助10
1秒前
1秒前
2秒前
molihuakai的应助被感性的若灵采纳,获得10
3秒前
3秒前
晨儿完成签到 ,获得积分10
3秒前
3秒前
4秒前
其他人完成签到,获得积分10
4秒前
4秒前
4秒前
Hello的应助被LCA采纳,获得10
5秒前
王自信发布了新的文献求助10
5秒前
5秒前
搞怪的康完成签到,获得积分10
5秒前
5秒前
YININININI发布了新的文献求助10
5秒前
8787发布了新的文献求助10
6秒前
6秒前
DW的应助被等待的紫伊采纳,获得10
6秒前
6秒前
6秒前
苏志坤完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
在水一方的应助被shangchen采纳,获得10
7秒前
李爱国的应助被wanghongyue采纳,获得10
7秒前
冲冲发布了新的文献求助10
8秒前
finish完成签到,获得积分10
8秒前
8秒前
8秒前
卓若之发布了新的文献求助10
8秒前
hluuuuu发布了新的文献求助10
8秒前
我是老大的应助被王自信采纳,获得10
8秒前
卓若之发布了新的文献求助10
9秒前
9秒前
翧礼完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177976
求助须知:如何正确求助?哪些是违规求助? 9568743
关于积分的说明 21801098
捐赠科研通 7772739
什么是DOI,文献DOI怎么找? 3432595
关于科研通互助平台的介绍 2556742
邀请新用户注册赠送积分活动 2478128